Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based biopharmaceutical company Geron Corporation and the University of Edinburgh have entered into a collaboration to conduct preclinical safety and efficacy studies with three cell types derived from human embryonic stem cells.
Subscribe to our email newsletter
The cell types are hepatocytes for the treatment of liver failure and osteoblasts and chondrocytes for the treatment of musculoskeletal disorders, including osteoarthritis, bone fractures and osteoporosis.
The studies, based at the University’s Centre for Regenerative Medicine, will be under the direction of Professor John Iredale, Dr Phil Newsome, Dr Brendon Noble and Professor Hamish Simpson.
“We are continuing our research activity in the UK because we know there is a pool of knowledgeable and talented human embryonic stem cells (hESC) scientists there. We are now sponsoring six UK-based hESC R&D programs. Moreover, in addition to the scientific talent and the general receptivity in the UK for hESC technology, there is funding support,” said David Greenwood, Geron’s executive vice president and chief financial officer.